Citing recent drug recalls due to Burkholderia cepacia complex (BCC), the FDA Monday reminded manufacturers of the need to establish procedures designed to prevent objectionable microorganism contamination of nonsterile drugs, use scientifically sound and appropriate acceptance criteria and test procedures, test in-process materials during production and investigate any failure to meet specifications.